Takabatake T, Ohta H, Yamamoto Y, Maekawa M, Arai S, Hattori N, Nomura G
Int J Clin Pharmacol Ther Toxicol. 1982 Aug;20(8):346-52.
The antihypertensive effect of a new calcium antagonist, nicardipine hydrochloride (YC-93), was studied in 47 mild to moderate essential hypertensives. YC-93 (30-60 mg/day) was administered orally alone for 8 weeks (Group I, 31 patients) or in combination with diuretics, beta blockers, or both (Group II, 16 patients). Blood pressure was reduced from 173.6 +/- 2.2/103.5 +/- 1.7 to 139.7 +/- 2.0/87.2 +/- 1.1 mmHg in Group I and from 172.9 +/- 3.9/108.9 +/- 2.9 to 140.5 +/- 2.3/89.5 +/- 2.5 mm Hg in Group II. Pulse rate was not altered in Group I but increased transiently in Group II. The side effects seen in seven patients were mostly related to the vasodilatation and were generally transient and mild. These results indicate that YC-93 is an effective antihypertensive drug for the treatment of essential hypertension.
对47例轻度至中度原发性高血压患者研究了一种新型钙拮抗剂盐酸尼卡地平(YC - 93)的降压效果。YC - 93(30 - 60毫克/天)单独口服8周(I组,31例患者)或与利尿剂、β受体阻滞剂联合使用(II组,16例患者)。I组血压从173.6±2.2/103.5±1.7降至139.7±2.0/87.2±1.1毫米汞柱,II组血压从172.9±3.9/108.9±2.9降至140.5±2.3/89.5±2.5毫米汞柱。I组脉搏率未改变,II组脉搏率短暂升高。7例患者出现的副作用大多与血管扩张有关,通常短暂且轻微。这些结果表明,YC - 93是治疗原发性高血压的有效降压药物。